Wade AJ - Search Results

1

Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients.

Roder C, Cosgrave C, Mackie K, Roberts SK, Hellard ME, Wade AJ, Doyle JS. Roder C, et al. Among authors: wade aj. Viruses. 2023 Mar 31;15(4):913. doi: 10.3390/v15040913. Viruses. 2023. PMID: 37112893 Free PMC article.

2

Chlamydia trachomatis prevalence in heterosexual men in Melbourne: a community-based study.

Wade AJ, Hocking JS, Hellard ME. Wade AJ, et al. Sex Health. 2007 Jun;4(2):137-8. doi: 10.1071/sh07008. Sex Health. 2007. PMID: 17524293

3

The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.

Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME. Wade AJ, et al. PLoS One. 2015 Nov 12;10(11):e0142770. doi: 10.1371/journal.pone.0142770. eCollection 2015. PLoS One. 2015. PMID: 26562516 Free PMC article.

4

A systematic review of community based hepatitis C treatment.

Wade AJ, Veronese V, Hellard ME, Doyle JS. Wade AJ, et al. BMC Infect Dis. 2016 May 16;16:202. doi: 10.1186/s12879-016-1548-5. BMC Infect Dis. 2016. PMID: 27184661 Free PMC article.

5

A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.

Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M. Wade A, et al. Aust Fam Physician. 2017;46(4):235-240. Aust Fam Physician. 2017. PMID: 28376580 Free article.

6

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.

Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN). Lubel J, et al. Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168. Antivir Ther. 2017. PMID: 28422043

7

Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.

Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Scott N, et al. Int J Drug Policy. 2017 Sep;47:107-116. doi: 10.1016/j.drugpo.2017.07.006. Epub 2017 Aug 7. Int J Drug Policy. 2017. PMID: 28797497

8

Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C.

Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME. Wade AJ, et al. J Viral Hepat. 2018 Sep;25(9):1089-1098. doi: 10.1111/jvh.12910. Epub 2018 May 8. J Viral Hepat. 2018. PMID: 29660212

9

Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.

Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M. Scott N, et al. J Virus Erad. 2018 Apr 1;4(2):108-114. J Virus Erad. 2018. PMID: 29682303 Free PMC article.

10

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.

Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME. Wade AJ, et al. Trials. 2018 Jul 16;19(1):383. doi: 10.1186/s13063-018-2768-3. Trials. 2018. PMID: 30012192 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page